Truncated ErbB2 receptor enhances ErbB1 signaling and induces reversible, ERK-independent loss of epithelial morphology

International Journal of Cancer

Volumn 94, Issue 2, 2001, Pages 185-191

  Egeblad, Mikala ^a   Mortensen, Ole H ^a   Jäättelä, Marja ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

EGFR; ErbB2; MAP kinase; Morphology

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GENE PRODUCT; MITOGEN ACTIVATED PROTEIN KINASE; TYROSINE KINASE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL INVASION; CELL MOTILITY; CELL STRUCTURE; ENZYME ACTIVATION; EPITHELIUM; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; EPITHELIAL CELLS; FEMALE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 0035888069     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1459     Document Type: Article

References (35)

1. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
2. Switching signals on or off by receptor dimerization
3. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer
4. NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: Role of PI3 kinase and p38 MAP kinase pathways
5. The ErbB signaling network: Receptor heterodimerization in development and cancer
6. Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion
7. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma
8. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene
9. c-erbB-2 in serum of patients with breast cancer
10. NH2-terminally truncated HER-2/neu protein: Relationship with shedding of the extracellular domain and with prognostic factors in breast cancer
11. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells
12. Matrix metalloproteinase inhibitors
13. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells
14. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters
15. Advanced mammalian gene transfer: High titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line
16. High-frequency transformation of human repair-deficient cell lines by an Epstein-Barr virus-based cDNA expression vector
17. Cell death induced by TNF or serum starvation is independent of ErbB receptor signaling in MCF-7 breast carcinoma cells
18. 2 in breast carcinoma cells
19. Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation
20. A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells
21. Tumor-inhibitory monoclonal antibodies to the HER-2/neu receptor induce differentiation of human breast cancer cells
22. Isolation of the Neu/HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells
23. Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth facto
24. Specificity of receptor tyrosine kinase signaling: Transient vs. sustained extracellular signal-regulated kinase activation
25. Extracellular signal-regulated kinase activity is sustained early during human cytomegalovirus infection
26. Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development
27. Conditional expression of the ErbB2 oncogene elicits reversible hyperplasia in stratified epithelia and upregulation of TGFα expression in transgenic mice
28. ErbB-2 amplification inhibits downregulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors
29. Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation
30. Domain-specific interactions between the p185(neu) and epidermal growth factor receptor kinases determine differential signaling outcomes
31. BIBX1382BS, but not AG1478 or PD153035, inhibits the ErbB kinases at different concentrations in intact cells
32. Transactivation of the EGF receptor mediates IGF-1-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells
33. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage
34. Proteases as prognostic markers in cancer
35. Metalloproteinases and tissue inhibitors of metalloproteinases